C797S, T790M and sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR.

BACKGROUND

Detection of sensitizing and p.T790M and p.C797S resistance mutations is particularly important for non-small cell lung cancer (NSCLC) patient therapy management. Non-invasive blood-based monitoring of these mutations may pave the way to a fine-tuned personalized treatment. Digital PCR has emerged as an extremely sensitive method to detect rare mutations, however its major limitation is the number of hotspots that can be simultaneously differentiated.

METHODS

We developed a 6-color digital PCR assay for the detection and quantification of 19 most prevalent sensitizing and resistance mutations and evaluated this assay on 82 tumor and plasma samples from NSLC patients.

RESULTS

Limits of detection (LOD) for the 6-color digital PCR assay were assessed on serial dilutions of DNA standards. We found that the 6-color assay enabled detection of mutant fractions as low as 1 mutant in 1025 wild-type molecules, depending on the mutation targeted, when assayed in a background of 10 000 wild-type DNA copies. mutant allelic fraction was also measured on tumor and plasma samples by 6-color digital PCR, and displayed a highly significant correlation with next generation sequencing and 3-color digital PCR. Lastly, the 6-color digital PCR assay was performed on several longitudinal plasma samples from four patients and revealed levels of sensitizing and resistance mutations that reflected well the course of the disease.

CONCLUSION

This 6-color Crystal digital PCR assay could represent a robust solution using digital PCR for the monitoring of mutations.